Orbimed Advisors Llc bought $5.5M of Shattuck Labs (STTK)
Executed Aug 25 2025, disclosed Sep 3 2025, 8 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Sep 2 2025), the stock returned +141.4% (delay-adjusted); from the execution session (Aug 25 2025), +156.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Orbimed Advisors Llc (Director) filed 15 Form 4 reports as a reporting entity in the trailing twelve months (7 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Sionna Therapeutics, Inc. (SION). Across 7 priced purchase filings, the average 21-session return was +16.9% from execution and +18.9% from disclosure (delay-adjusted; derived). The largest single filing was $38.9M of ELVN (858,646 sh across 3 lots, as filed), executed Jun 22.
Healthcare · Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→